CG MedTech, a leading company specializing in orthopedic implant research and manufacturing, is accelerating its global expansion with a renewed focus on Latin America. The company has entered four new markets—Puerto Rico, the Dominican Republic, Nicaragua, and Peru—broadening its global footprint from 19 to 23 countries. These additions build on its existing presence in key markets such as Mexico, Brazil, China, Ukraine, Chile, Vietnam, and Colombia.
In 2024, CG MedTech’s overseas sales rose by 9% year-over-year, driven by its entry into new Latin American markets and increased demand for its flagship products. Among the top-performing products are the ANAX 5.5 posterior fixation system, the Velofix TLIF interbody fusion cage, and the Velofix SA standalone anterior fixation system—all of which continue to see rising global demand.
The ANAX 5.5 stands out for its versatility in various surgical settings, earning trust from international surgeons for its robust fixation and precision-engineered design. The ANAX OCT, used in cervical spine fusion, is also gaining traction globally, thanks to its reliable stability and precise performance.
Further expansion in Latin America is planned for two recently launched products: the Innoverse, a next-generation fixation system introduced in late 2023 in South Korea and the U.S., and the UniSpace Stand-Alone C Cage, a 3D-printed cervical fusion cage.
“Expanding collaborations with global medical professionals and developing market-tailored solutions are critical to building international competitiveness,” said Ju Mi Chung, CEO of CG MedTech. “To establish a strong foothold in our newly entered Latin American markets, we plan to intensify educational and hands-on training programs for local healthcare providers.”
CG MedTech actively participates in major international orthopedic and spinal conferences in the U.S., engaging with global surgeons and distributors to showcase the latest advancements. The company is also scaling up its educational efforts through cadaveric workshops and online webinars—delivering in-depth training on surgical techniques and device applications to both new and existing customers.
Looking ahead to 2025, CG MedTech plans to launch new posterior fixation solutions across North and South America, while further expanding its surgeon education programs in the region. Backed by cutting-edge innovation and a growing global network, the company is committed to strengthening its leadership in the international spine implant market.
Meanwhile, CG MedTech has signed an exclusive supply agreement with Johnson & Johnson MedTech for NOVOSIS Trauma. Under the deal, CG MedTech will be the sole supplier of NOVOSIS Trauma to Johnson & Johnson MedTech, which will begin distribution and sales in South Korea.